The current review highlights advances in the use of direct-acting antiviral (DAA) agents in the treatment of hepatitis C virus (HCV) in chronic kidney disease (CKD) stages G4-5, end-stage renal disease, and kidney transplantation. The use of DAA to facilitate kidney transplantation of HCV negative recipients with kidneys from HCV-infected donors and in the management of HCV-related cryoglobulinemia are also reviewed.

中文翻译：

---

慢性肾病丙型肝炎病毒管理的进展。

本综述重点介绍了直接作用抗病毒 (DAA) 药物在慢性肾病 (CKD) G4-5 期、终末期肾病和肾移植中治疗丙型肝炎病毒 (HCV) 的进展。还回顾了使用 DAA 促进 HCV 阴性受者的肾移植以及来自 HCV 感染供体的肾脏以及 HCV 相关冷球蛋白血症的管理。